Mirum Pharmaceuticals announced that the FDA has approved a label expansion for Livmarli oral solution for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis, or PFIC. The expanded label includes use in PFIC patients 12 months and older as well as the higher concentration formulation of LIVMARLI evaluated in the MARCH Phase 3 study.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals: EU approves LIVMARLI for patients with PFIC
- Mirum Pharmaceuticals submits new drug application to FDA for chenodiol
- Biotech Alert: Searches spiking for these stocks today
- Mirum Pharmaceuticals price target raised to $66 from $48 at Stifel
- Mirum Pharmaceuticals price target raised to $39 from $34 at Baird